Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Biopharma SRL
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least
1 year prior to Baseline
Stable HS for at least 2 months prior to Screening and also at the Baseline Visit
Inadequate response to at least a 3-month study of an oral antibiotic for treatment of HS
Total abscess and inflammatory nodule count \>=3 at the Baseline Visit
Subject must agree to daily use (and throughout the entirety of the study) of 1 pre-specified over-the-counter topical antiseptics on their HS lesions
Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose
Male subjects must be willing to use a method of contraception when sexually active, up till 20 weeks after the last administration of study medication
You may not be if
Prior treatment with anti-IL17s or participation in an anti-IL17 study
Previously received anti-TNFs
Subject requires, or is expected to require, opioid analgesics for any reason (excluding tramadol)
Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline Visit
Subject received systemic non-biologic therapies for HS with potential therapeutic impact for HS less than 28 days prior to Baseline Visit
Draining fistula count \>20 at the Baseline Visit
Diagnosis of inflammatory conditions other than HS
